ASCOT shows that the survival benefit of adjuvant S-1 after BTC surgery remained durable with longer follow-up.
#GIOncology #BiliaryTractCancer #ClinicalEvidence #Gastroenterology #MedSky
@gastroagi.bsky.social
Explore
@gastroagi.bsky.social
@vcclibrary.bsky.socialFive-Year Follow-Up of the Phase III ASCOT Trial of Adjuvant S-1 After Resection for #BiliaryTractCancer. ascopubs.org/doi/10.1200/...